Kairos Pharma Ltd
KAPA
Detailliertes Diagramm anzeigen
0.912USD
+0.044+5.12%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
16.18MMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
+5.12%
5 Tage
-20.02%
1 Monat
-28.20%
6 Monate
+12.11%
Seit Jahresbeginn
-40.01%
1 Jahr
-32.46%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung von Kairos Pharma Ltd
Währung: USD Aktualisiert: 2025-11-04Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ sehr gesund. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Trotz einer sehr schwachen Entwicklung des Aktienmarktes zeigt das Unternehmen starke Fundamentaldaten. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Kairos Pharma Ltd Bewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
3
Analysten
Kaufen
Aktuelles Rating
8.333
Kursziel
+725.08%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Kairos Pharma Ltd Highlights
HöhepunkteRisiko
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its products consist of five pre-clinical or clinical-trial stage drug candidates developed by it and designed to target immune response, and two therapeutic agents developed by its Enviro Therapeutics, Inc. (Enviro) subsidiary and designed to increase anti-tumor response in conjunction with cancer therapies by addressing resistance to these agents. Its product portfolio includes a variety of technologies licensed by its Enviro subsidiary and consists of compositions and methods for treating diseases and conditions by targeting CD105 and depleting mitochondrial DNA from the circulation. Its products include KROS 101, 102, 201, 301, 401, ENV 105 and 205.
high_profit_growth
high_profit_growth_desc%!(EXTRA string=0.00)
valuation_overestimated
valuation_overestimated_desc%!(EXTRA string=PE, string=-2.49)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=286.70K, string=85.47%)
Kairos Pharma Ltd Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Kairos Pharma Ltd Informationen
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its products consist of five pre-clinical or clinical-trial stage drug candidates developed by it and designed to target immune response, and two therapeutic agents developed by its Enviro Therapeutics, Inc. (Enviro) subsidiary and designed to increase anti-tumor response in conjunction with cancer therapies by addressing resistance to these agents. Its product portfolio includes a variety of technologies licensed by its Enviro subsidiary and consists of compositions and methods for treating diseases and conditions by targeting CD105 and depleting mitochondrial DNA from the circulation. Its products include KROS 101, 102, 201, 301, 401, ENV 105 and 205.
BörsenkürzelKAPA
UnternehmenKairos Pharma Ltd
CEODr. John S. Yu, M.D.
Websitehttps://kairospharma.com
Verwandte Finanzinstrumente
+4.24%
-0.56%
+0.06%
-0.79%
+0.26%
+0.57%
+7.88%
-0.16%
-0.01%
+0.43%
+0.03%
-0.10%
+0.84%
+1.66%
-0.20%
+0.07%
0.00%
+2.51%
+3.02%
-4.01%Beliebte Symbole
